Anteris Technologies Ltd - Strategic SWOT Analysis Review

Anteris Technologies Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Report Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The analyst’s summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Anteris Technologies Ltd (Anteris Technologies), formerly Admedus Ltd, designs, develops, and commercializes innovative medical devices and technologies with a focus on tissue engineering and immunotherapies. The company's primary activities include conducting clinical trials, securing regulatory approvals, and manufacturing its flagship product, the DurAVR THV, a transcatheter heart valve (THV) for treating aortic stenosis. Anteris also collaborates with v2vmedtech inc to develop a minimally invasive treatment for mitral and tricuspid valve regurgitation. The DurAVR THV, made using Anteris' patented ADAPT anti-calcification tissue technology, is used by healthcare professionals in the treatment of severe aortic stenosis. The company's products are distributed globally. The company's target markets include Australia, Europe, the US, Canada, Singapore, Malaysia, India, Hong Kong, and the Middle East. Anteris Technologies is headquartered in Brisbane, Queensland, Australia.

Anteris Technologies Ltd Key Recent Developments

• Feb 26, 2026: Anteris Reports 2025 Financial Results and Corporate Update
• Jan 20, 2026: Anteris Technologies Global Corp. Proposes $200 Million Public Offering and Medtronic Strategic Investment
• Nov 17, 2025: Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves
• Oct 27, 2025: Anteris Technologies Reports One-Year Clinical Outcomes for DurAVR THV at TCT 2025

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.